1. Home
  2. PGY vs DNTH Comparison

PGY vs DNTH Comparison

Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGY
  • DNTH
  • Stock Information
  • Founded
  • PGY 2016
  • DNTH 2015
  • Country
  • PGY United States
  • DNTH United States
  • Employees
  • PGY N/A
  • DNTH N/A
  • Industry
  • PGY Finance: Consumer Services
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGY Finance
  • DNTH Health Care
  • Exchange
  • PGY Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • PGY 863.7M
  • DNTH 606.2M
  • IPO Year
  • PGY N/A
  • DNTH N/A
  • Fundamental
  • Price
  • PGY $23.25
  • DNTH $19.94
  • Analyst Decision
  • PGY Strong Buy
  • DNTH Strong Buy
  • Analyst Count
  • PGY 9
  • DNTH 8
  • Target Price
  • PGY $23.61
  • DNTH $53.00
  • AVG Volume (30 Days)
  • PGY 2.5M
  • DNTH 364.2K
  • Earning Date
  • PGY 08-07-2025
  • DNTH 08-07-2025
  • Dividend Yield
  • PGY N/A
  • DNTH N/A
  • EPS Growth
  • PGY N/A
  • DNTH N/A
  • EPS
  • PGY N/A
  • DNTH N/A
  • Revenue
  • PGY $1,076,961,000.00
  • DNTH $6,524,000.00
  • Revenue This Year
  • PGY $20.61
  • DNTH N/A
  • Revenue Next Year
  • PGY $13.33
  • DNTH N/A
  • P/E Ratio
  • PGY N/A
  • DNTH N/A
  • Revenue Growth
  • PGY 23.69
  • DNTH 102.36
  • 52 Week Low
  • PGY $8.20
  • DNTH $13.37
  • 52 Week High
  • PGY $23.93
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • PGY 74.41
  • DNTH 57.13
  • Support Level
  • PGY $21.11
  • DNTH $17.88
  • Resistance Level
  • PGY $23.45
  • DNTH $23.37
  • Average True Range (ATR)
  • PGY 1.32
  • DNTH 1.35
  • MACD
  • PGY 0.13
  • DNTH 0.31
  • Stochastic Oscillator
  • PGY 93.40
  • DNTH 48.96

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: